TTC7A Antibody

What is TTC7A and what cellular compartments should I expect to detect it in when using antibodies?

TTC7A is a conserved protein containing 9 tetratricopeptide repeat (TPR) domains that function in multiprotein scaffolding . When using antibodies against TTC7A, you should expect to detect the protein in multiple cellular compartments:

• Plasma membrane: Immunohistochemical staining of healthy intestinal biopsy specimens confirms TTC7A localizes at the plasma membrane where it functions as a scaffolding protein .

• Cytosol: TTC7A is diffusely localized in the cytosol but translocates to the plasma membrane when co-expressed with EFR3 .

• Nucleus: Recent evidence shows TTC7A is an essential nuclear protein that binds to chromatin, particularly at actively transcribed regions .

For comprehensive detection, consider using subcellular fractionation methods followed by western blotting to verify antibody detection in each compartment. For microscopy applications, co-staining with compartment-specific markers will help confirm localization patterns.

Why are TTC7A antibodies important tools for investigating intestinal and immune disorders?

TTC7A antibodies are critical research tools because:

• Disease mechanism investigation: Mutations in TTC7A cause severe intestinal disorders including multiple intestinal atresias (MIA) and very early onset inflammatory bowel disease (VEOIBD), often accompanied by combined immunodeficiency (CID) .

• Diagnostic validation: Over 50 patients with more than 20 distinct disease-causing TTC7A mutations have been identified . Antibodies can help confirm protein expression patterns or loss in patient samples.

• Phenotype correlation: TTC7A staining of patient biopsy samples with truncating mutations shows total loss of protein, consistent with the increased phenotypic severity in patients with MIA-CID .

• Cellular pathology assessment: TTC7A-deficient cells show distinctive morphological changes, including disrupted cobblestone morphology, impaired adhesion, increased apoptosis, and inverted apicobasal polarity .

When analyzing patient specimens, antibody selection should target domains preserved in the specific mutation being studied, or use multiple antibodies targeting different epitopes to ensure comprehensive analysis.

What are the key experimental controls needed when using TTC7A antibodies?

Proper controls are essential for reliable TTC7A antibody-based experiments:

Remember that TTC7A expression is comparable in many tissues , so careful selection of relevant biological controls is crucial for interpreting experimental results accurately.

How can TTC7A antibodies be used to investigate its dual role in plasma membrane scaffolding and nuclear functions?

TTC7A has recently been shown to function both as a plasma membrane scaffolding protein and as a nuclear factor regulating chromatin organization . A multi-method approach using TTC7A antibodies can help investigate these distinct functions:

• Proximity ligation assays (PLA): Use TTC7A antibodies with antibodies against known binding partners:

  • For membrane scaffolding: Pair with PI4KIIIα, FAM126A, and EFR3B antibodies to detect interactions in the PI4KIIIα complex

  • For nuclear functions: Pair with chromatin-associated proteins or histones to detect nuclear interactions

• Chromatin immunoprecipitation (ChIP) using TTC7A antibodies to identify genomic binding sites, followed by sequencing (ChIP-seq) to map TTC7A chromatin occupation patterns .

• Co-immunoprecipitation coupled with mass spectrometry to identify novel TTC7A interacting proteins in different cellular compartments.

• Immunofluorescence microscopy with spectral unmixing to simultaneously track TTC7A localization to different compartments under various cellular conditions.

• Fluorescence recovery after photobleaching (FRAP) with fluorescently tagged antibody fragments to measure TTC7A dynamics between compartments.

These approaches can help determine how TTC7A's localization shifts in response to cellular signals and whether its membrane and nuclear functions are coordinated or independent.

How can TTC7A antibodies help elucidate the mechanistic link between TTC7A deficiency and aberrant RhoA/ROCK signaling in intestinal epithelial cells?

TTC7A deficiency has been linked to abnormal RhoA/ROCK signaling that affects epithelial cell polarity and cytoskeletal dynamics . TTC7A antibodies can be employed in several strategic approaches to investigate this relationship:

• Proximity ligation assays (PLA): Use TTC7A antibodies alongside antibodies against RhoA pathway components to determine if there's direct or indirect interaction.

• Immunoprecipitation followed by kinase assays: Immunoprecipitate TTC7A complexes to determine if they contain components that regulate RhoA activity.

• Phospho-specific western blotting: After TTC7A immunoprecipitation, probe for phosphorylated downstream effectors of ROCK (like myosin light chain and ezrin-radixin-moesin proteins) to assess pathway activation .

• Immunofluorescence imaging: Co-stain for TTC7A and actin cytoskeletal structures in wild-type and TTC7A-deficient cells treated with or without ROCK inhibitors.

• Organoid culture imaging: Perform immunofluorescence in patient-derived intestinal organoids using TTC7A antibodies alongside polarity markers before and after ROCK inhibitor treatment (10 μmol/L Y-27632) .

The organoid approach is particularly powerful as studies have shown that exposure of TTC7A patient organoids to ROCK inhibitor corrected polarity defects and increased proliferation , suggesting a direct mechanistic link between TTC7A and the RhoA/ROCK pathway.

What methodologies can be employed to investigate the differential effects of TTC7A mutations on protein expression versus function using antibodies?

The diverse spectrum of TTC7A mutations produces variable phenotypes that likely reflect differences in protein expression versus functional impairment . To distinguish these effects:

• Epitope mapping strategy: Use multiple antibodies targeting different domains of TTC7A:

  • N-terminal antibodies: Detect truncated proteins

  • TPR domain-specific antibodies: Assess preservation of scaffolding domains

  • C-terminal antibodies: Evaluate full-length expression

• Quantitative immunoblotting: Compare absolute protein levels across patient samples with different mutations to establish expression thresholds that correlate with disease severity.

• Immunoprecipitation coupled with functional assays:

  • PI4P production assay after TTC7A immunoprecipitation to assess scaffolding function

  • Chromatin binding assay after TTC7A immunoprecipitation to assess nuclear function

• Subcellular fractionation: Determine if specific mutations alter TTC7A distribution between membrane, cytosolic, and nuclear compartments.

• Protein stability assessment: Pulse-chase experiments with cycloheximide treatment followed by immunodetection to determine if mutations affect protein half-life.

This multi-faceted approach can help establish whether specific mutations result in pure loss-of-function, partial function, or aberrant function, potentially explaining the heterogeneous phenotypes observed in patients with different TTC7A mutations.

What are the optimal fixation and antigen retrieval methods for TTC7A immunohistochemistry in intestinal tissues?

Optimizing TTC7A detection in intestinal tissues requires careful consideration of fixation and antigen retrieval methods:

When working with intestinal tissues from TTC7A-deficient patients, it's crucial to note that immunohistochemical staining of samples with truncating mutations shows complete loss of protein . This finding suggests nonsense-mediated decay of TTC7A mRNA transcripts and highlights the need for additional molecular methods (like RT-PCR) alongside immunostaining to fully characterize patient samples.

How can researchers differentiate between TTC7A and its paralog TTC7B using antibody-based approaches?

TTC7A has a paralog, TTC7B, with 49.47% sequence identity , which can complicate antibody-based detection. To ensure specific detection of TTC7A:

• Epitope selection: Choose antibodies targeting regions with minimal homology between TTC7A and TTC7B. Conduct sequence alignment to identify divergent regions.

• Validation in knockout/knockdown systems:

  • Test antibodies in TTC7A-knockdown cells (verify signal reduction)

  • Test in TTC7B-knockdown cells (verify signal persistence)

  • Ideally, test in double knockdown systems

• Expression pattern analysis: TTC7A and TTC7B have distinct tissue expression patterns:

  • TTC7A: Widely expressed across multiple tissues during development

  • TTC7B: Higher expression in the cerebral cortex and cerebellum during development; in adults, higher in brain, fat, and small bowel

• Isoform-specific PCR controls: Perform RT-PCR using isoform-specific primers alongside antibody-based detection to confirm specificity.

• Peptide competition assays: Use synthetic peptides unique to each paralog to determine antibody specificity.

• Western blot mobility: TTC7A (858 amino acids) and TTC7B may show subtle differences in electrophoretic mobility that can help distinguish them.

Remember that TTC7B may have functional redundancy with TTC7A, particularly in the small bowel , which could explain tissue-specific effects of TTC7A mutations despite its broad expression pattern.

What are the technical considerations for using TTC7A antibodies in chromatin immunoprecipitation (ChIP) experiments?

Recent research has revealed TTC7A's crucial role as a nuclear factor binding to chromatin . For successful TTC7A ChIP experiments:

• Crosslinking optimization:

  • Standard formaldehyde crosslinking (1%, 10 minutes) for protein-DNA interactions

  • Consider dual crosslinking with disuccinimidyl glutarate (DSG) followed by formaldehyde for enhancing detection of indirect chromatin associations

• Sonication parameters:

  • Optimize to generate 200-500bp fragments

  • Monitor sonication efficiency by agarose gel electrophoresis

  • Excessive sonication may disrupt TTC7A epitopes

• Antibody selection criteria:

  • Use antibodies validated for ChIP applications

  • Consider antibodies targeting different epitopes to confirm binding patterns

  • Determine optimal antibody concentration (typically 2-5μg per reaction)

• Controls:

  • Input chromatin (pre-immunoprecipitation sample)

  • IgG control (same species as TTC7A antibody)

  • Positive control (antibody against known chromatin-associated protein)

  • TTC7A-depleted cells as negative control

• Sequential ChIP considerations:

  • For investigating co-occupancy with transcription factors, perform sequential ChIP

  • Order of antibody addition may affect efficiency

• Data analysis:

  • ChIP-seq data should be analyzed for enrichment at actively transcribed regions

  • Compare binding patterns with transcriptome data to correlate with gene expression

Since TTC7A preferentially binds to actively transcribed regions , consider including ChIP for active histone marks (H3K4me3, H3K27ac) in parallel experiments to correlate TTC7A binding with chromatin activation state.

How can TTC7A antibodies be used to study the immunological features of TTC7A deficiency?

TTC7A deficiency causes combined immunodeficiency (CID) alongside intestinal disease in approximately 75% of patients . TTC7A antibodies can be valuable tools for investigating the immunological aspects:

• Thymic epithelial cell analysis:

  • Patient thymus samples show hypoplasia and abnormal distribution of epithelial cells

  • Use TTC7A antibodies with thymic epithelial markers to analyze how TTC7A deficiency affects thymic architecture

• Lymphocyte development studies:

  • TTC7A-deficient patients display profound, generalized lymphocytopenia

  • Use flow cytometry with TTC7A intracellular staining alongside lymphocyte lineage markers to track developmental abnormalities

• Lymphocyte function assessment:

  • TTC7A-deficient lymphocytes show increased proliferation, adhesion, and migration

  • Compare TTC7A localization in normal versus patient lymphocytes during functional assays

• PI4P pathway analysis in immune cells:

  • TTC7A acts as a scaffolding protein in the PI4KIIIα complex

  • Use co-immunoprecipitation with TTC7A antibodies to assess complex formation in immune cells

• ROCK pathway activation:

  • TTC7A deficiency alters ROCK signaling in lymphocytes

  • Use phospho-specific antibodies against ROCK targets alongside TTC7A staining

When studying patient samples, remember that the specific mutation may affect antibody binding, so validate antibody reactivity or use multiple antibodies targeting different epitopes.

What approaches can be used to study TTC7A's role in maintaining epithelial apicobasal polarity using antibodies?

TTC7A deficiency disrupts epithelial apicobasal polarity, a key feature of intestinal pathology in affected patients . Antibody-based approaches to investigate this include:

• 3D organoid culture imaging:

  • Generate intestinal organoids from patient biopsies or TTC7A-knockdown cells

  • Use TTC7A antibodies alongside polarity markers (E-cadherin, ZO-1, basolateral markers)

  • Image before and after ROCK inhibitor treatment (10 μmol/L Y-27632)

• Co-immunoprecipitation of polarity complexes:

  • Use TTC7A antibodies to pull down associated proteins

  • Probe for components of polarity complexes (Par, Crumbs, Scribble)

  • Compare complex formation in normal versus TTC7A-deficient cells

• Ratiometric polarity assessment:

  • Quantify the ratio of apical:basolateral markers in TTC7A-positive versus TTC7A-negative regions

  • Create correlation plots of TTC7A intensity versus polarity marker distribution

• Live-cell imaging with antibody fragments:

  • Use fluorescently labeled Fab fragments against TTC7A and polarity markers

  • Track real-time changes in localization during polarity establishment

• Calcium switch assays:

  • Monitor TTC7A localization during de novo junction formation following calcium restoration

  • Assess if TTC7A relocalization precedes or follows polarity establishment

Patient organoid studies have shown that TTC7A-deficient cells display inverted apicobasal polarity that can be normalized by ROCK inhibition , suggesting a mechanistic link between TTC7A, RhoA/ROCK signaling, and polarity establishment that can be further explored using these approaches.

How can researchers use TTC7A antibodies to investigate the relationship between TTC7A's nuclear functions and intestinal disease phenotypes?

TTC7A has recently been identified as a nuclear factor with important functions in chromatin organization and gene regulation , but how these functions relate to intestinal pathology remains unclear. To investigate this relationship:

• Chromatin structure analysis:

  • Use TTC7A antibodies in ChIP-seq to map genomic binding sites

  • Compare chromatin accessibility (ATAC-seq) in TTC7A-positive versus TTC7A-deficient regions

  • Investigate if TTC7A binds to regulatory elements of genes involved in intestinal epithelial development

• Histone modification patterns:

  • Perform sequential ChIP for TTC7A and various histone modifications

  • Analyze if TTC7A loss correlates with specific epigenetic changes at intestinal-specific genes

• Nucleosome distribution:

  • TTC7A deficiency causes unbalanced cellular distribution of histones

  • Use super-resolution microscopy with TTC7A and histone antibodies to visualize nucleosome organization

• Transcriptional regulation:

  • Perform RNA-seq after TTC7A knockdown/knockout in intestinal epithelial cells

  • Use TTC7A ChIP-seq data to correlate binding with expression changes

  • Focus analysis on genes involved in epithelial polarity and intestinal barrier function

• Genome instability assessment:

  • TTC7A loss induces genome instability

  • Use immunofluorescence for DNA damage markers alongside TTC7A staining

  • Investigate if genomic regions bound by TTC7A are protected from instability

This multilayered approach can help establish whether TTC7A's nuclear functions are directly linked to intestinal phenotypes or represent a separate aspect of its function that contributes to disease pathogenesis through different mechanisms.